{
  "symbol": "AMGN",
  "year": 2024,
  "period": "Q3",
  "competition_summary": [
    {
      "competitor": "Litigation Amgen Inc.",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "Sandoz Inc.",
      "mentions": 2,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "the U.S. District Court",
      "mentions": 3,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "Sandoz",
      "mentions": 6,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "FDA",
      "mentions": 2,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "Amgen",
      "mentions": 8,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "the New Jersey District Court",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "Amgen\u2019s \u2018736 Patent",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "the United States Sandoz",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "the \u2019736 Patent",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "ABP",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "the Judicial Panel on Multidistrict Litigation",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "Regeneron",
      "mentions": 2,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "District Court",
      "mentions": 2,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "the Delaware District Court",
      "mentions": 4,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "the U.S. Court of Appeals",
      "mentions": 2,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "the Third Circuit",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "the Third Circuit Court",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "the Third Circuit Court\u2019s",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "U.S. Tax Litigation",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "Related Matters Amgen Inc. & Subsidiaries",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "IRS",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "Company",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "the U.S. Tax Court",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "ChemoCentryx",
      "mentions": 4,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "the Ninth Circuit",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "ANALYSIS OF FINANCIAL CONDITION",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "MD&A",
      "mentions": 3,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "SEC",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    },
    {
      "competitor": "EPS",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Sandoz Inc., et al. On April 29, 2024, the U.S. District Court for the District of New Jersey (the New Jersey District Court) entered judgment in the lawsuit pending against Sandoz Inc. based on Sandoz\u2019s submission to the FDA of a Biologics License Application seeking approval to market and sell a biosimilar version of Amgen\u2019s Prolia and XGEVA products (\u201cSandoz\u2019s biosimilar denosumab products\u201d). The complaint asserted infring"
    }
  ]
}